Form 4: Thermo Fisher Scientific CEO Marc Casper Reports Adjustment in Performance-Based Restricted Stock Units

Thermo Fisher Scientific's CEO, Marc Casper, reports an adjustment in his holdings of common stock due to the performance-based vesting of restricted stock units.

Summary

• On February 28, 2025, Marc Casper, CEO of Thermo Fisher Scientific, reported a change in his beneficial ownership of company stock.
• This change is due to the vesting of performance-based restricted stock units (RSUs).
• The third tranche of these RSUs was adjusted downward by 30% due to the company's relative total shareholder return (TSR) over the period from January 1, 2022, to December 31, 2024.
• As a result, Casper received 1,656 fewer shares than initially reported.
• He disposed of 1,522.464 shares at $528.96 and 3,825.453 shares at $528.96.
• Following these transactions, Casper directly owns 115,173.623 shares of common stock.
• Casper also indirectly owns shares through the Alison Casper 2020 Irrevocable Trust (11,300 shares), Floral Park Associates, Inc. (14,608 shares), and the MNC 2020 Irrevocable Trust (5,000 shares).

Sentiment

Score: 5

Explanation: The document itself is neutral, reporting a factual adjustment in stock ownership. However, the downward adjustment in RSU vesting due to TSR performance is a slightly negative signal.

Negatives

• The downward adjustment of 30% in the RSU tranche suggests that Thermo Fisher Scientific's relative total shareholder return (TSR) was below expectations during the measurement period.

Risks

• The adjustment in RSU vesting based on TSR highlights the risk associated with performance-based compensation, where payouts can be significantly affected by market conditions and company performance.

Industry Context

Executive compensation packages often include performance-based components like RSUs to align management's interests with those of shareholders. The adjustment based on TSR is a common mechanism to ensure that executives are rewarded for delivering superior returns relative to peers.

Comparison to Industry Standards

• Performance-based equity compensation is a common practice among publicly traded companies, particularly in the science and technology sectors.
• Companies like Danaher, Agilent, and Illumina also utilize TSR-based vesting conditions for executive equity awards.
• The specific TSR targets and vesting schedules vary depending on the company's size, industry, and overall compensation philosophy.
• A 30% downward adjustment suggests that Thermo Fisher's TSR performance was notably below its peer group during the specified period.

Stakeholder Impact

• Shareholders may be concerned about the company's relative TSR performance, as it resulted in a reduced equity award for the CEO.
• This could potentially impact investor sentiment and the company's stock price.

Key Dates